Synergistic RNA Immunogen Delivery Systems

This inventive concept integrates lipid-formulated RNA encoding immunogens with distinct technologies such as AI, IoT, blockchain, and new materials to create more powerful and effective immunization systems.

The original patent disclosed lipid formulations with RNA encoding immunogens, but it had limitations in terms of scalability, tracking, and personalization. This new inventive concept addresses these limitations by combining the original lipid-formulated RNA with cutting-edge technologies to create more efficient, trackable, and personalized immunization systems.

The new system comprises a lipid-formulated RNA encoding an immunogen, wherein the RNA is synthesized using a hybrid alphavirus genome and the lipid particles are tagged with a blockchain-based identifier for tracking and verification. Alternatively, the RNA can be synthesized using a machine learning algorithm to optimize the immunogen sequence and the lipid particles can be embedded with an IoT sensor for real-time monitoring. Additionally, the composition can comprise a lipid-formulated RNA encoding an immunogen and a nanomaterial-based adjuvant, wherein the RNA is synthesized using a 3D-printed template and the nanomaterial is designed to enhance the immunogenicity of the RNA. The system can also be designed for personalized immunization, wherein the RNA is synthesized using a patient's genetic data and the lipid particles are designed to target specific immune cells using AI-powered analytics.

The new claims introduce novel combinations of technologies that were not previously disclosed in the original patent. The use of hybrid alphavirus genome, machine learning algorithms, blockchain-based identifiers, IoT sensors, 3D-printed templates, and AI-powered analytics for personalized immunization are all new and non-obvious features that provide a significant improvement over the original patent.

Other embodiments of the inventive concept could include using different types of RNA synthesis methods, such as CRISPR-Cas9 gene editing, or alternative nanomaterial-based adjuvants. The system could also be designed for use in different applications, such as cancer treatment or infectious disease prevention.

The synergistic RNA immunogen delivery systems have significant commercial potential in the vaccine and immunotherapy markets. The ability to provide personalized, trackable, and effective immunization systems could revolutionize the way we approach disease prevention and treatment. The target industries could include pharmaceutical companies, biotech companies, and healthcare providers.